[Form 4] BridgeBio Pharma, Inc. Insider Trading Activity

Rhea-AI Filing Summary

The Form 4 filing discloses that Hannah A. Valantine, M.D., a director of BridgeBio Pharma, Inc. (BBIO), sold a total of 4,707 shares of BBIO common stock on 26-Jun-2025 at weighted-average prices ranging from $44.01 to $44.14 per share.

• Direct holdings: Two separate sales of 876 shares (avg. $44.1099) and 1,542 shares (avg. $44.01) reduced Dr. Valantine’s direct ownership from 9,883 shares to 7,465 shares.
• Indirect (spousal) holdings: Two sales of 398 shares (avg. $44.1263) and 1,891 shares (avg. $44.0303) lowered spousal indirect holdings from 2,687 shares to 398 shares.
• Total remaining beneficial ownership: 7,863 shares (7,465 direct + 398 indirect).
• The filing uses transaction code “S” indicating open-market sales. Weighted-average price ranges are provided; detailed price breakdowns are available upon request, per footnotes 1 and 2.

No derivative security transactions were reported. No 10b5-1 trading plan is indicated, and there are no acquisitions or option exercises in this filing.

The magnitude of the sale represents a partial reduction of the director’s position rather than a complete exit, and the company’s overall share count is unaffected. The information is limited to insider activity; it does not include operational or financial performance data.

Positive

• None.

Negative

• Director sold 4,707 shares, reducing total beneficial ownership by approximately 37%, which can be viewed as a mildly negative insider-sentiment signal.

Insights

Securities Analyst

TL;DR – Director trims stake by 4,707 shares at ~$44; modest size, neutral-to-slightly negative sentiment.

Dr. Valantine sold roughly 37% of her combined direct and indirect position (4,707 of 12,570 pre-sale shares) at market prices near $44. Because the transactions were open-market sales without an accompanying 10b5-1 plan, they can be interpreted as discretionary. While insider selling often raises caution flags, the dollar value (≈$207k) is modest relative to BBIO’s daily trading volume and market capitalization. No derivatives were exercised or created, suggesting this is a straightforward liquidity event rather than a strategic repositioning. Overall impact on valuation is minimal, but the selling may carry a mildly negative signal for sentiment-sensitive investors.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Valantine Hannah

(Last) (First) (Middle)

C/O BRIDGEBIO PHARMA, INC.

3160 PORTER DR., SUITE 250

(Street)

PALO ALTO CA 94304

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Pharma, Inc. [ BBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/26/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/26/2025		S		876	D	$44.1099(1)	9,007	D
Common Stock	06/26/2025		S		1,542	D	$44.01	7,465	D
Common Stock	06/26/2025		S		398	D	$44.1263(2)	2,289	I	By Spouse
Common Stock	06/26/2025		S		1,891	D	$44.0303	398	I	By Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the weighted average sale price of the shares sold from $44.025 to $44.14 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

2. Represents the weighted average sale price of the shares sold from $44.12 to $44.13 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

	/s/ Hannah A. Valantine, M.D.	06/30/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many BBIO shares did Director Hannah Valantine sell?

She sold 4,707 shares of BridgeBio Pharma common stock on 26-Jun-2025.

At what price were the BBIO shares sold?

Weighted-average prices ranged from $44.01 to $44.14 per share.

How many BBIO shares does the director still own after the sale?

Dr. Valantine now beneficially owns 7,863 shares (7,465 direct and 398 indirect via spouse).

Were any derivative securities involved in this Form 4 filing?

No. Table II shows no derivative transactions; only open-market sales of common stock were reported.

Was the sale made under a Rule 10b5-1 trading plan?

The filing does not indicate that the transactions were executed under a 10b5-1 plan.